Author: Ravi Shankar

BANGKOK, Sept. 29, 2026 (GLOBE NEWSWIRE) — NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $1.25 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consists of 17,857,143 Ordinary Shares or Pre-Funded Warrants in lieu thereof. The public offering price per Common Share is $0.07 (or $0.06999 for each Pre-Funded Warrant, which is equal to the public offering price per Ordinary Share to be sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of Ordinary Shares in the offering will be decreased on a one-for-one basis.

Aggregate gross proceeds to the Company are expected to be approximately $1.25 million. The transaction is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in the cell-sorting business, and general corporate purposes.

Aegis Capital Corp. is acting as the exclusive placement agent for the offering. Han Kun Law Offices LLP is acting as U.S. counsel to the Company. Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.

A registration statement on Form F-1 (No. 333-298442) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 20, 2026 was declared effective by the SEC on September 28, 2026. The offering is being made only by means of a prospectus. A final prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010. Before investing in this offering, interested parties should read in their entirety the prospectus, which provides more information about the Company and such offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NewGen

NewGenIVF Group is a technology-forward, diversified growth company, pursuing opportunities across real estate development, digital asset innovation and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in the UAE’s Ras Al Khaimah Emirate; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. NewGenIVF’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com

BEIJING, Sept. 28, 2026 (GLOBE NEWSWIRE) — Julong Holding Limited (“Julong” or the “Company”) (Nasdaq: JLHL), a growth-oriented provider of intelligent integrated solutions, today announced that, on September 28, 2026, it entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors for a private placement (the “Private Placement”) of the Company’s securities.

Under the terms of the Securities Purchase Agreement, the Company agreed to issue and sell (i) 750,000 Class A ordinary shares (the “Class A Ordinary Shares”), par value US$0.0001 per share, of the Company (the “Initial Shares”), at a purchase price of US$0.300 per share, and (ii) 2,250,000 pre-funded warrants to purchase up to an aggregate of 2,250,000 Class A Ordinary Shares (the “Pre-Funded Warrants,” together with the Initial Shares, the “Securities”), at a purchase price of US$0.299 per pre-funded warrant. The Pre-Funded Warrants have an exercise price of US$0.001 per share, are immediately exercisable, and may be exercised at any time until exercised in full. The aggregate gross proceeds of the Private Placement are US$897,750.

The Private Placement is expected to close on or about September 29, 2026, subject to satisfaction or waiver of the conditions precedent set forth in the Securities Purchase Agreement. Net proceeds from the Private Placement, after deducting offering expenses, are approximately US$828,000. The Company intends to use such proceeds for general corporate purposes. The Company’s management retains discretion over the use and timing of the proceeds.

The Securities offered in this Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The investors represented that they were accredited investors within the meaning of Rule 501(a) of Regulation D of the Securities Act and were acquiring the Securities for investment only and with no present intention of distributing any of such Securities or any arrangement or understanding regarding the distribution thereof. Additional details regarding the Private Placement are set forth in the Company’s Current Report on Form 6-K filed with the U.S. Securities and Exchange Commission.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Julong

Founded in 1997, Julong is a growth-oriented professional provider of intelligent integrated solutions to public utilities, commercial properties, and multifamily residential properties operating at scale in China. The Company’s comprehensive suite of intelligent integrated solutions includes systems for intelligent security, fire protection, parking, toll collection, broadcasting, identification, data room, emergency command, and city management. Since its inception, Julong has focused on the successful and on-time execution of complex projects, through its “deliveries before deadline” and “customers first” initiatives. As Julong continues to cross-sell its service and solution offerings and advance its purpose-built technologies, the Company is well-positioned to achieve economies of scale and capture future opportunities.

For more information, please visit: ir.julongzx.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “will,” “would,” “may,” “expects,” “anticipates,” “aims,” “future,” “continues,” “could,” “should,” “target,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements, and include, but are not limited to, statements regarding the expected closing of the Private Placement and the use of proceeds therefrom. Forward-looking statements involve inherent risks and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the risk that the Private Placement may not close on the anticipated timeline or at all, and other factors discussed under “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

Investor Relations:
Email: ir@julongzx.com

Piacente Financial Communications
Jenny Cai
Tel: +86 (10) 6508-0677
Email: julong@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: julong@thepiacentegroup.com

All measurable sequencing metrics show profound improvement over Platinum Pro

BRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum^® Pro instrument. Using a developmental sequencing kit that detects 18 amino acids, Proteus significantly outperformed Platinum Pro across every key measure, from sequencing scale and accuracy to peptide identification and protein sequence coverage, even though the Proteus instrument, consumable, loading protocol and analysis software are still in development and not yet fully optimized. The data will be presented by Jeff Hawkins, President and Chief Executive Officer, at a lunchtime seminar at the 2026 World HUPO Congress in Singapore on Tuesday, September 29, 2026, at 12:15 Singapore Time (SGT) in Room 330.

“These interim results show that Proteus is a fundamentally superior platform technology, not simply a larger version of Platinum Pro,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “Proteus improves every fundamental driver of sequencing performance, including scale, signal quality, conversion and accuracy, and those gains compound into dramatically more data. What makes these results even more encouraging is that this Proteus system has not yet been fully optimized, and we expect further improvements ahead of launch.”

In a control peptide study designed to evaluate fundamental performance independent of sample preparation, Proteus delivered a median of 30 times more alignments than Platinum Pro from a single chamber, identified all six control peptides in every run, and achieved a 4.8-fold lower median false discovery rate (1.36% in Proteus versus 6.58% in Platinum Pro). Based on these single-chamber results, the Company projects that a full four-chamber Proteus run could deliver approximately 60 times more alignments than a two-chamber Platinum Pro run. In protein mixtures prepared with a commercial library prep kit, Proteus identified 1.6 to 2.0 times more peptides than Platinum Pro. Further, in a 24-protein panel not previously sequenced on either platform, Proteus detected all 24 proteins, compared with an average of 20.3 on Platinum Pro, and detected 4.3 times more amino acids per run, with higher per-residue detection across the amino acids measured, including cysteine and histidine, which were detected only on Proteus. A copy of the presentation will be available in the Events & Presentations section of the Quantum-Si investor relations website, and an audio recording will be added once available.

Figure 1: Reported alignments per single-chamber run, control peptide study (n = 4 runs per platform)

Figure 2: 24-protein panel results from a single chamber, proteins not previously sequenced on either platform

About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time, kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products, services and applications, its anticipated cash runway, the anticipated timing of product launches and product capabilities, including the expected launch of Proteus in the second quarter of 2027, the expected performance of Proteus relative to Platinum Pro, including projected full-run performance, and the expected amino acid detection capabilities of Proteus, including the expected detection of all 20 amino acids in the commercial kit at launch, the Company’s current belief regarding remaining technical challenges associated with Proteus commercialization, the expected timing and successful completion of system integration, optimization, verification, validation and launch-readiness activities, the expected benefits of the Company’s development-process, organizational and cost-control actions, including the reduction in force, and any financial guidance.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Many of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company’s ongoing leadership transitions and succession planning; the Company’s ability to successfully implement organizational changes, including workforce reductions, cost-control actions and development-process improvements, without disrupting product development, launch readiness, employee retention or customer engagement; the possibility that additional technical, integration, performance, reliability, verification, validation or launch-readiness challenges may arise or take longer or cost more to address than expected; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future, including Proteus; the potential attributes and benefits of the Company’s commercialized Platinum Pro protein sequencing instruments and kits and the Company’s other products (including Proteus) once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s defense and initiation of litigation matters; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor and Media Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/b0d73d5e-1892-4005-8408-5bdb14565852

https://www.globenewswire.com/NewsRoom/AttachmentNg/7746d376-a9ee-470f-bac3-57aa70ceb458

SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held on October 1-4, 2026, in Vienna, Austria.

EIS Presentation Details
Session: EURETINA Innovation Spotlight – Inherited and Rare Retinal Diseases
Title: Belite Bio Company Overview
Presenter: Hendrik Scholl, M.D., Chief Medical Officer, Belite Bio
Date and Time: September 30, 2026, 2:28 – 3:06 p.m. CEST
Location: Vienna Congress & Convention Center, Room 1/Hall A

Euretina Presentation Details
Session: EURETINA Free Paper 47 – Inherited Retinal Disease
Title: Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt Disease
Presenter: Michel Michaelides, M.D., Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom
Date and Time: October 4, 2026, 1:20 – 1:27 p.m. CEST
Location: Vienna Congress & Convention Center, Free Paper Forum 2

About Tinlarebant (a/k/a LBS-008)

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.

About Stargardt Disease

STGD1 is the most common inherited macular dystrophy in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of high-resolution retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no approved treatments for STGD1.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the Company’s new drug application for tinlarebant for the treatment of STGD1 was accepted by the U.S. Food and Drug Administration (FDA), with priority review, in August 2026. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027. Tinlarebant is also currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
ir@belitebio.com

— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —

— Application supported by SAFFRON, the first global Phase III trial to demonstrate statistically significant and clinically meaningful improvements in progression-free and overall survival in this setting —

— SAFFRON builds on evidence from the SACHI Phase III and SAVANNAH Phase II trials —

HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that AstraZeneca has submitted a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for ORPATHYS^® (savolitinib) plus TAGRISSO^® (osimertinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have MET overexpression or amplification, and who had disease progression on or after an epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.

The NDA is supported by the global SAFFRON Phase III trial. SAFFRON showed ORPATHYS^® plus TAGRISSO^® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (“PFS”) and overall survival (“OS”) versus doublet platinum-based chemotherapy in patients who progressed on treatment with TAGRISSO^®. The safety profile was consistent with the known profiles of each medicine, and there were no new safety concerns. These results will be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology (ESMO) Congress 2026.

Third-generation EGFR tyrosine kinase inhibitors (“TKIs”) have significantly improved outcomes for patients with EGFRm NSCLC. However, MET overexpression or amplification is one of the most common mechanisms of resistance on third-generation EGFR-TKI treatment. MET-driven progression is associated with poor prognosis, and there remains a significant unmet need for effective and well-tolerated treatment options in this setting.

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “This filing is an important step toward potentially bringing ORPATHYS^® plus TAGRISSO^® to patients in the US, after its approval in China based on the SACHI Phase III trial. The success of the global SAFFRON Phase III trial reflects the long-standing collaboration between HUTCHMED and AstraZeneca in addressing MET-driven progression in EGFR-mutated lung cancer. We remain committed to supporting the regulatory review and making this biomarker-directed, chemotherapy-free oral combination available to eligible patients.”

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and is commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.¹ Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.² Approximately 75% of NSCLC patients are diagnosed with advanced disease.³ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.^​4,5,6

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁷ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.^7,8 An estimated 34% of tumors will develop high levels of MET overexpression or amplification after progression on a third-generation EGFR TKI.¹

About SAFFRON

SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of ORPATHYS^® (300 mg twice daily) added to TAGRISSO^® (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO^®. The trial enrolled patients in 230 centers across 29 countries, including in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.

Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. ​In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.

About ORPATHYS^®

ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO^®

TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS^®, the further clinical development for ORPATHYS^®, its expectations as to whether any studies on ORPATHYS^® would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS^®, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS^® for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS^®. In addition, as certain studies rely on the use of other drug products such as TAGRISSO^® as combination therapeutics with ORPATHYS^®, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

REFERENCES

1         World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed August 2026.

2         American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.

3         Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.

4         Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6:2800-2812.

5         Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First- Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29:2121-2127.

6         Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013;66:79-89.

7         Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074)

8         Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Energy Income Fund (TSX – ENI.UN) (the “Fund”) is pleased to announce that unitholders will have the opportunity to redeem up to 253,384 units (the “Units”) of the Fund.

The annual redemption date has been set for November 27, 2026. Units will be redeemed for an amount per Unit equal to net asset value less redemption costs equal to 5% of net asset value per Unit plus applicable taxes (as contemplated in the Fund’s declaration of trust which is available on the Fund’s SEDAR+ profile at www.sedarplus.ca). If requests for redemptions exceed 253,384 Units, Units will be redeemed on a pro rata basis.

In order to redeem their Units, holders must deliver a redemption notice to their broker sufficiently in advance to ensure that such notice is then delivered to the Fund’s transfer agent by no later than 5:00 p.m. (Toronto time) on October 30, 2026. Unitholders wishing to participate in the redemption should contact their brokers if they have any questions about how to provide a redemption notice.

Units tendered for this redemption will be entitled to receive the October 2026 distribution which, as previously announced, will be paid on November 16, 2026.

On or about December 4, 2026, the Fund will announce the annual redemption price and the Fund expects to pay the redemption proceeds to redeeming unitholders on or before December 18, 2026.

For further information, please contact Artemis Investment Management Limited, the manager of the Fund, at (647) 494-0338 or email at info@artemisfunds.ca or visit our website at www.artemisfunds.ca.   

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Citadel Income Fund (TSX – CTF.UN) (the “Fund”) is pleased to announce that unitholders will have the opportunity to redeem up to 262,689 units (the “Units”) of the Fund.

The annual redemption date has been set for November 27, 2026. Units will be redeemed for an amount per Unit equal to net asset value less redemption costs equal to 5% of net asset value per Unit plus applicable taxes (as contemplated in the Fund’s declaration of trust which is available on the Fund’s SEDAR+ profile at www.sedarplus.ca). If requests for redemptions exceed 262,689 Units, Units will be redeemed on a pro rata basis.

In order to redeem their Units, holders must deliver a redemption notice to their broker sufficiently in advance to ensure that such notice is then delivered to the Fund’s transfer agent by no later than 5:00 p.m. (Toronto time) on November 6, 2026. Unitholders wishing to participate in the redemption should contact their brokers if they have any questions about how to provide a redemption notice.

Units tendered for this redemption will be entitled to receive the October 2026 distribution which, as previously announced, will be paid on November 16, 2026.

On or about December 4, 2026, the Fund will announce the annual redemption price and the Fund expects to pay the redemption proceeds to redeeming Unitholders on or before December 18, 2026.

For further information, please contact Artemis Investment Management Limited, the manager of the Fund, at (647) 494-0338 or email at info@artemisfunds.ca or visit our website at www.artemisfunds.ca.

GRAND FALLS-WINDSOR, Newfoundland and Labrador, Sept. 28, 2026 (GLOBE NEWSWIRE) — First Atlantic Nickel & Cobalt Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P210) (“First Atlantic” or the “Company”) is pleased to announce that it has closed a no-warrant, non-brokered private placement (the “Offering”) for aggregate gross proceeds of $3,767,700.25. Following this closing, the Company has raised aggregate gross proceeds of approximately $9.925 million from financings completed in September 2026. The Offering consisted of 2,333,667 flow-through common shares of the Company (each, an “FT Share”) at a price of $0.75 per FT Share, and 2,570,000 charity flow-through common shares of the Company (each, a “CFT Share”) at a price of $0.785 per CFT Share. Each FT Share and CFT Share qualifies as a “flow-through share” within the meaning of subsection 66(15) of the Income Tax Act (Canada). No warrants were issued in connection with the Offering.

In connection with the Offering, a strategic investor exercised its participation right under an existing Investor Rights Agreement. The investor’s participation was limited so that, following completion of the Offering, its beneficial ownership of the Company’s issued and outstanding common shares will not exceed 9.99%, remaining below the 10% early warning reporting threshold.

First Atlantic welcomes calls directly from shareholders and prospective investors. For questions about the Company or the Pipestone XL project, or simply to learn more, investors are invited to call Rob Guzman, Investor Relations, at +1-844-592-6337 or email rob@fanickel.com.

Proceeds will fund follow-up and expansion drilling at the Alloy Max North and Alloy Max South Zones, the Company’s new large-scale awaruite discovery extending up to approximately 7.7 kilometres north of the RPM Zone. Alloy Max spans approximately 4 kilometres of strike and up to 1.5 kilometres in width, larger than the RPM Zone, and both the Alloy Max discovery hole, XL-26-15, and XL-26-16, the deepest hole to date at Pipestone XL, ended in visible awaruite mineralization. Proceeds will also fund definition drilling and metallurgical test work at the RPM, Alloy Max South and Alloy Max North Zones.

Upgrades to project access roads and trails are expected to enable faster, year-round drilling and a scale-up of exploration activities along the approximately 30-kilometre mineralized trend, including targets north of Alloy Max toward the historic Atlantic Lake Zone that were previously reachable only by helicopter or have never been fully explored. In each case, these expenditures will be funded only to the extent they qualify as Qualifying Expenditures (as defined below).

PIPESTONE XL: A DISTRICT-SCALE NICKEL-COBALT ALLOY PROJECT

Pipestone XL is First Atlantic’s wholly owned, district-scale project spanning the entire 30-kilometre Pipestone Ophiolite Complex in central Newfoundland, a belt of ultramafic rock enriched in nickel, cobalt, and chromium. The Project hosts multiple zones of awaruite (Ni₃Fe) mineralization, including RPM, Alloy Max, Super Gulp, Atlantic Lake, and Chrome Pond. The RPM Zone is the most advanced, with drilling having outlined magnetically recoverable awaruite over more than 1.2 kilometres of strike and more than 800 metres of width. Drilling is ongoing at Alloy Max, a second large-scale zone spanning approximately 4 kilometres of strike and up to 1.5 kilometres in width, making it larger than the RPM Zone.

Awaruite at Pipestone XL is the product of serpentinization, which drives sulphur out of the system and leaves a sulphur-free alloy which carries no acid mine drainage risk and can be concentrated by the Company’s ONSHORE MAX™ process without smelting, roasting, or high-pressure acid leaching. This smelter-free pathway addresses the midstream bottleneck in North America, where the United States has no operating nickel smelters and only two remain in Canada, and supports a vertically integrated supply chain moving directly from mine to downstream battery refining, stainless steel and specialty alloy production. The Company is also evaluating secondary chromium mineralization as a potential co-product, along with low-carbon Engineered Mineral Hydrogen (EMH) in partnership with VEMA Hydrogen¹.

Figure 1: Map showing multiple target zones across the 30-kilometer nickel trend over total magnetic intensity (TMI) at the Pipestone XL Project highlighting the showing, the 30-kilometre Pipestone Ophiolite Complex and the RPM, Alloy Max, Super Gulp, Atlantic Lake and Chrome Pond Zones.

Pipestone XL is located in an established infrastructure corridor with year-round road access, nearby high-voltage transmission and clean hydroelectric power from the Bay d’Espoir generating station. It is also located approximately 200 kilometres from Gander International Airport and Vale’s Long Harbour nickel processing plant. This positioning aligns with growing U.S. and allied policy focus on critical mineral supply chains, including nickel’s addition to the U.S. critical minerals list in 2022, the January 2026 White House proclamation on processed critical minerals², the Company’s acceptance into the U.S. Defense Industrial Base Consortium³, and the June 2026 G7 Leaders’ Declaration naming nickel one of two pilot critical minerals for allied investment and offtake⁴.

Newfoundland and Labrador is consistently recognized as one of the world’s leading mining jurisdictions in the Fraser Institute’s Annual Survey of Mining Companies, ranking 7th globally on the Policy Perception Index in the most recent survey, published in February 2026, and placing in the global top 10 for overall investment attractiveness in each of the three prior surveys. Pipestone XL is positioned to become a secure and reliable North American source of nickel and cobalt for the stainless steel, electric vehicle, aerospace, and defense industries.

AWARUITE AT PIPESTONE XL: A SMELTER-FREE NICKEL-COBALT ALLOY (Ni₃Fe)

Awaruite is a naturally occurring, magnetic, sulphur-free nickel-iron-cobalt alloy (Ni₃Fe) containing approximately 77% nickel. Because it already exists in a metallic state, awaruite can be concentrated without smelting, roasting, or high-pressure acid leaching. Mineralogical and electron microprobe analysis at the Company’s RPM Zone has confirmed the awaruite averages 77.62% nickel and 1.69% cobalt, with grades as high as 86.68% nickel and 6.05% cobalt⁵.

Initial metallurgical test work using the Company’s ONSHORE MAX™ (Magnetic Alloy eXtraction) process upgraded rock samples from the project’s RPM Zone into a high-grade alloy concentrate averaging 67.4% nickel and grading up to 71.9% nickel and 1.76% cobalt⁶. Low-intensity magnetic separation first produced a magnetic concentrate grading approximately 1.6% nickel, which flotation then upgraded to the final concentrate. By comparison, a typical nickel concentrate grades 10% to 15% nickel, according to the Nickel Institute. This concentrate can move directly to downstream battery chemical refining or the manufacture of specialty alloys and stainless steel.

The absence of sulphur reduces acid mine drainage risk and related permitting challenges, positioning Pipestone XL to supply North American industries including stainless steel, electric vehicles, aerospace, and defence.

Figure 2: USGS quote on awaruite nickel-iron-cobalt alloy.

The gross proceeds of the Offering will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures,” as those terms are defined in the Income Tax Act (Canada) (the “Qualifying Expenditures”), in connection with the exploration programs described above at the Company’s Pipestone XL Nickel-Cobalt Alloy Project and exploration activities at its Ophiolite X Project in Newfoundland. The Company will incur the Qualifying Expenditures on or before December 31, 2027 and renounce them in favour of subscribers effective December 31, 2026.

All securities issued in connection with the Offering are subject to a statutory hold period of four months and one day, expiring on January 26, 2027 and January 29, 2027, under applicable Canadian securities laws. The Offering remains subject to final acceptance by the TSX Venture Exchange.

No finder’s fees were paid in connection with the Offering.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable state securities laws, and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.

INVESTOR INFORMATION

The Company’s common shares trade on the TSX Venture Exchange under the symbol “FAN”, on the OTCQB under the symbol “FANCF”, and on several German exchanges, including Frankfurt and Tradegate, under the symbol “P210”. Investors can get updates about First Atlantic by signing up to receive news via email and SMS text at www.fanickel.com.

QUALIFIED PERSON

Adrian Smith, P.Geo., a director and the Chief Executive Officer of the Company, is a qualified person as defined by NI 43-101. The qualified person is a member in good standing of the Professional Engineers and Geoscientists Newfoundland and Labrador (PEGNL) and is a registered professional geoscientist (P.Geo.). Mr. Smith has reviewed and approved the technical information disclosed herein.

ABOUT FIRST ATLANTIC NICKEL & COBALT CORP.

First Atlantic Nickel & Cobalt Corp. (TSXV: FAN | OTCQB: FANCF | FSE: P210) is a critical mineral exploration company in Newfoundland and Labrador developing the Pipestone XL Nickel-Cobalt (Ni-Fe-Co) Alloy Project. The project spans the entire 30-kilometre Pipestone Ophiolite Complex, where multiple zones, including RPM, Alloy Max, Super Gulp, Atlantic Lake and Chrome Pond, contain awaruite (Ni₃Fe), a naturally occurring magnetic nickel-iron-cobalt alloy of approximately 77% nickel with no sulphur and no sulphides, along with secondary chromium mineralization. Awaruite’s sulphur-free composition removes acid mine drainage risk, while its magnetic properties enable processing through magnetic separation and flotation, eliminating the electricity requirements, emissions and environmental impacts of conventional smelting, roasting or high-pressure acid leaching, while reducing dependence on overseas nickel processing infrastructure.

The U.S. Geological Survey recognized awaruite’s strategic importance in its 2012 Annual Report on Nickel, noting that these deposits may help alleviate prolonged nickel concentrate shortages since the natural alloy is much easier to concentrate than typical nickel sulphide. In 2026, initial metallurgical test work using the Company’s ONSHORE MAX™ (Magnetic Alloy eXtraction) process upgraded RPM Zone material into a high-grade alloy concentrate averaging 67.4% nickel and grading up to 71.9% nickel and 1.76% cobalt, demonstrating a smelter-free, mine-to-refinery pathway. First Atlantic is a member of the U.S. Defense Industrial Base Consortium. The Company is also advancing a parallel geologic hydrogen initiative at Pipestone XL, where the same serpentinization process that formed awaruite also generates natural hydrogen, and has signed a letter of intent with VEMA Hydrogen to jointly develop low-carbon Engineered Mineral Hydrogen (EMH) through a proposed 50/50 joint venture. The Pipestone XL project is located near existing infrastructure with year-round road access and proximity to hydroelectric power, providing favorable logistics for exploration and future development and strengthening First Atlantic’s role to establish a secure and reliable source of North American nickel and cobalt production for the stainless steel, electric vehicle, aerospace, and defense industries. This mission gained importance when the U.S. added nickel to its critical minerals list in 2022, recognizing it as a non-fuel mineral essential to economic and national security with a supply chain vulnerable to disruption.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward looking statements

Certain information contained in this news release constitutes “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking information”). Forward-looking information is often identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” and similar expressions.

Forward-looking information in this news release includes statements regarding: final acceptance of the Offering by the Exchange; the intended use of proceeds; the qualification of expenditures as Canadian exploration expenses and flow-through mining expenditures, the incurrence of those expenditures by December 31, 2027 and their renunciation in favour of subscribers effective December 31, 2026; the scope, timing and anticipated results of exploration and metallurgical programs at the Pipestone XL Nickel-Cobalt Alloy Project and Ophiolite X Project, including district-scale drilling, expansion of the RPM Zone and testing of newly identified targets; the potential capabilities, scalability and benefits of the ONSHORE MAX™ process; the potential to concentrate awaruite without smelting, roasting or high-pressure acid leaching; the suitability of concentrates for downstream refining and the manufacture of battery chemicals, specialty alloys and stainless steel; potential environmental and permitting benefits; and the potential for Pipestone XL to supply North American industrial markets.

This forward-looking information is based on management’s current expectations and assumptions, including that required regulatory approvals will be obtained; planned expenditures will satisfy applicable tax requirements and be incurred and renounced within the specified timelines; necessary permits, personnel, contractors, equipment and laboratory capacity will be available; exploration and metallurgical programs can be completed within anticipated budgets and schedules; further testing will support the applicability of initial metallurgical results to representative project material and larger-scale operations; any resulting concentrates will meet relevant downstream processing and customer specifications; and that further environmental studies will support the anticipated environmental benefits.

Forward-looking information is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These include failure to obtain regulatory approvals or complete additional financing; changes in market conditions, commodity prices, costs or the availability of financing; failure to incur sufficient qualifying expenditures within the required period, adverse tax determinations or changes in tax laws or their interpretation; exploration results that do not support anticipated mineralization or expansion targets; geological and metallurgical variability; the preliminary nature of test results and the risk that such results cannot be replicated at larger scale or achieved economically; concentrate impurities, recovery limitations or failure to meet downstream specifications; permitting delays, environmental liabilities and findings that differ from anticipated environmental benefits; operational, weather, equipment, contractor and laboratory delays; and other risks described in the Company’s continuous disclosure filings available on SEDAR+ at www.sedarplus.ca.

Initial metallurgical results do not establish commercial viability or guarantee future recoveries, concentrate quality or processing performance. There can be no assurance that the anticipated exploration, processing, environmental or commercial outcomes will be achieved.

Although management considers its expectations and assumptions reasonable as of the date of this news release, forward-looking information is not a guarantee of future performance. Readers are cautioned not to place undue reliance on it. Except as required by applicable securities laws, the Company undertakes no obligation to update forward-looking information to reflect subsequent events, circumstances or changes in expectations.

---

¹ https://fanickel.com/20260608-vema-hydrogen-and-first-atlantic-nickel-cobalt-sign-loi-to-develop-engineered-mineral-hydrogen-at-pipestone-xl-awaruite-project-in-newfoundland
² https://fanickel.com/20260115-first-atlantic-nickel-highlights-relevance-of-pipestone-xl-awaruite-nickel-cobalt-alloy-discovery-to-address-u-s–critical-mineral-supply-chain-vulnerabilities-identified-in-january-14-2026-white-house-proclamation
³ https://fanickel.com/20260331-first-atlantic-nickel-announces-acceptance-into-defense-industrial-base-consortium-dibc—pipestone-xl-smelter-free-nickel-cobalt-alloy-project-addresses-midstream-smelting-bottleneck-in-u-s–defense-supply-chain
⁴ https://fanickel.com/20260619-first-atlantic-nickel-cobalt-highlights-g7-leaders-declaration-on-critical-minerals-g7-names-nickel-one-of-only-two-pilot-minerals-for-a-new-allied-traceability-framework-moves-to-mobilize-equity-investment-and-offtake-and-establishes-a-critical-
⁵ https://fanickel.com/20260521-first-atlantic-nickel-cobalt-reports-electron-microprobe-analysis-returning-77-62-nickel-and-1-69-cobalt-in-awaruite-at-the-rpm-zone-pipestone-xl-project-a-rare-naturally-magnetic-ni-fe-co-high-grade-alloy-mineralogically-capable-of-bypassing-mid
⁶ https://fanickel.com/20260624-first-atlantic-nickel-cobalt-produces-high-grade-alloy-concentrate-up-to-71-9-nickel-and-1-76-cobalt-from-its-pipestone-xl-nickel-cobalt-alloy-project-using-its-first-ever-onshore-max-magnetic-alloy-extraction-recovery-concentration-process-unvei

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/560ed2db-31fa-48a5-983a-084c7dec90f3
https://www.globenewswire.com/NewsRoom/AttachmentNg/d77e19f0-b6e3-4af2-b1e0-1f592726fc26

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Entrée Resources Ltd. (TSX:ETG; OTCQB:ERLFF – the “Company” or “Entrée”) today issued the following letter to shareholders from Chris Adams, President and CEO.

Dear Fellow Shareholders,

Autumn is off to a very busy start at Entrée. Since my appointment as President and CEO in July, I have been focused on building personal relationships with many of our larger shareholders, our Joint Venture partner, and other key stakeholders. Most importantly, I traveled to Mongolia at the start of September to personally see our interest in the Oyu Tolgoi copper-gold project and to meet Entrée’s Mongolian employees as well as in-country representatives of Rio Tinto and Oyu Tolgoi LLC, the Minister of Industry and Mineral Resources, and certain leaders in the business community. We also welcomed an experienced new director to our Board in August following Stephen Scott’s retirement. With this important groundwork completed, I would like to take the opportunity to introduce myself, update you on recent developments, and give you a preview of several initiatives that we have underway at Entrée.

Before I begin, on behalf of the Board of Directors and our teams in Vancouver and Ulaanbaatar, I would like to convey our deepest sympathies to the family and friends of our former President and CEO, Stephen Scott, who passed away suddenly earlier this month. Steve was a valued colleague and friend, and he will be greatly missed.

Introduction

For those shareholders I haven’t yet had the pleasure to meet I’d like to introduce myself and provide some insight as to how I became involved with Entrée.

I joined the Board and the Audit Committee as an independent director in January 2026, when Dr. Michael Price retired after many years of service. Prior to this I spent over 30 years working for CIBC Capital Markets and Macquarie Group in all aspects of mining finance including equity research, equity capital markets, mergers and acquisitions, debt finance and investing in growth-stage mining companies. I was initially attracted to Entrée for its carried interest in a portion of the world-class Oyu Tolgoi copper-gold project managed by Rio Tinto, the potential for near-term production on the Joint Venture property, and Entrée’s experienced Board and management team.

Following the announcement in May of Steve’s upcoming retirement, I had the honor of being selected by the Board to lead the management team at the head office in Vancouver, working alongside a group of dedicated professionals. As CEO, I remain focused on engagement with Oyu Tolgoi project stakeholders and the Government of Mongolia in order to finish the work Steve started. Resolution of outstanding issues to enable the resumption of Hugo North Extension Lift 1 underground mining would mark a pivotal moment in Entrée’s 25-year history, unlocking value for Entrée shareholders and the people of Mongolia alike.

Development of Hugo North Extension Lift 1 on the Shivee Tolgoi license area at Oyu Tolgoi.
Source: Entrée Resources – Sept 2026

Recent Board Refreshment Initiatives

Entrée has a robust Board refreshment program in place to ensure the collective skill set possessed by its members meets the evolving needs of the Company. In August, Sarah Strunk was appointed to the Board as an independent director. Sarah has served on the board of international copper producer Teck Resources since 2022 and was a director of Arizona Sonoran Copper until its acquisition in June 2026 by Hudbay Minerals in an all-share transaction valued at approximately US$1.5 billion. Sarah is also a highly accomplished business and finance lawyer with extensive experience in the mining industry, serving as a director and shareholder of the law firm Fennemore Craig, P.C. based in their San Diego office.

Richard Williams, who was elected as a director at our 2026 Annual General Meeting of shareholders held in June, is also a valuable addition to our Board. Richard is currently the CEO and a director of Winshear Metals Corp. (TSX-V:WINS, FRA:9HR) and was formerly the CEO and a director of Cornish Metals PLC (AIM:TIN) for nine years until March 2024. Richard is a geologist by training and brings extensive experience acquired over a 35-year career with exploration and development companies in both emerging and developed jurisdictions.

Our Board, with its great balance of retained institutional knowledge possessed by our Chair, Alan Edwards, and other longer tenured directors, complemented by the fresh voices and perspectives brought by Sarah, Richard and me, is well-positioned to guide Entrée forward.

Visit to Mongolia

One of my immediate priorities as the new President and CEO was to visit Mongolia and the Oyu Tolgoi project in order to spend time with our valued employees, Joint Venture partner and project stakeholders in-country, and to gain a more detailed and holistic understanding of the interest we hold in this world-class asset.

In early September, Oyu Tolgoi LLC hosted me and our CFO, Duane Lo, on a site visit to see the project and meet their management team. We were impressed with the scale, efficiency, and longevity of the operations, and the expertise of their people. In addition to the site visit, we also held productive meetings with other project stakeholders and local business leaders in Ulaanbaatar, including the Mongolian Minister of Industry and Mineral Resources and our in-country advisors.

Oyu Tolgoi underground inclined conveyor in Mongolia.
Source: B. BAYANJAVZAN – 2025/11/19

A key part of our in-country community engagement is our commitment to fund scholarships for students studying mining related programs at three of Mongolia’s leading universities. A very gratifying part of the trip was visiting two of the universities to meet their faculty leaders and to hear about the positive impact our scholarship program has had on the students and the country.

Representatives of Entrée and Mongolia University of Science & Technology, where Entrée provides scholarships.
Source: Entrée Resources Ltd. files May 2024 and Sept 2026

Updated Technical Report

We are targeting Q1 2027 for completion and release of a technical report discussing Oyu Tolgoi LLC’s updated resource model for Hugo North Extension Lifts 1 and 2. The update follows significant Lift 2 in-fill drilling and other work undertaken since 2022 on the Joint Venture property. Oyu Tolgoi LLC has advised us that an updated Lift 1 underground mine plan and production schedule, which will be incorporated into our technical report, are expected to be completed in Q4 2026. The updated technical report will also use current costs and forecast metal prices that reflect today’s market environment (compared to an assumed copper price of US$3.25/lb and a gold price of US$1,591/oz used in the 2021 report) allowing investors to better understand the potential value of our interest in Hugo North Extension Lift 1. The technical report will include a new resource estimate for Hugo North Extension Lift 2, where in-fill drilling designed to support a feasibility study has increased the level of resource confidence. Our QPs continue to review and validate data as it is received from our Joint Venture partner.

LEFT: Lift 2 in-fill drilling on the Shivee Tolgoi license.
Source: Entrée Resources – Sept 2026
RIGHT: Road train delivering ore to underground crushers.
Source: Entrée Resources – Sept 2026

Update on Joint Venture License Transfers

Key to our success as an organization is the progress of the transfer of the Joint Venture mining licenses to Oyu Tolgoi LLC. We continue to engage with the Government of Mongolia in cooperation with our Joint Venture partner and our respective advisers.

In June, the Joint Venture partners updated the valuation calculations for the licenses and paid the license transfer tax to the Mongolian tax authority in accordance with applicable laws. The parties continue to engage with the Mongolian tax authority to obtain the tax payment certificate required to be submitted to the Mineral Resources and Petroleum Authority of Mongolia for registration of the transfer of the licenses.

We note reports that Rio Tinto CEO Simon Trott was in Mongolia in September to formalize an agreement to lower the management fees and shareholder loan interest rate in the 2011 Oyu Tolgoi Amended and Restated Shareholders Agreement. Rio Tinto also reaffirmed its commitment to work with the Government of Mongolia towards a dividend for both Oyu Tolgoi LLC shareholders (Rio Tinto and State-owned Erdenes Oyu Tolgoi LLC) in 2027. Rio Tinto had publicly announced on June 30 its agreement to work together with the Government of Mongolia to bring forward distributions to shareholders, as well as to resolve matters relating to the Joint Venture license areas in a timely manner.

Subject to completion of the license transfers, we intend to continue working with Oyu Tolgoi LLC to convert our Joint Venture interest into a simplified structure of equivalent economic value. Conversion would be subject to Toronto Stock Exchange acceptance and satisfaction of Canadian regulatory requirements applicable to a related party transaction.

September 11, 2026 joint briefing by Uchral Nyam-Osor, Prime Minister of Mongolia, and Simon Trott, Chief Executive Officer of Rio Tinto.
Source: https://www.montsame.mn/

Shareholder Feedback

One of my top priorities has been to engage with our shareholders and invite their constructive feedback about the Company. Since my appointment in July, I have had the opportunity to interact with many shareholders representing the overwhelming majority of our shares. We appreciate the support and confidence of our investors, as evidenced by the strong support for all items at our recent Annual General Meeting.

However, several shareholders commented they would like to receive more frequent updates from us. As a result of that feedback, we are working to increase our investor relations activities and attendance at conferences, and we look forward to connecting with our shareholders more frequently and through more channels than in the past. Consider this letter the first action on this item, not the last.

Outlook

My experiences over the past few months have only reinforced my belief that we have a bright future ahead of us. Our Company is built on a solid foundation underpinned by an interest in a world-class asset. Our leadership team has been refreshed and re-energized by the addition of new members with complementary skills, connections, and ideas. At the same time, we continue to leverage the collective knowledge, experience, and long-standing relationships of our directors and senior executives.

Copper trades near all-time highs and has an excellent outlook as mainstream investors begin to appreciate the implications of constrained supply and high demand growth rates driven by electrification. Oyu Tolgoi is ramping up to be the fourth largest copper mine in the world with bottom-quartile operating costs and a large gold by-product, and our interest is projected to generate cash flow for many decades to come.

I encourage you to follow our progress and look for regular updates. We always welcome your input and feedback, and you can contact us at info@EntreeResourcesLtd.com or 1.866.368.7330.

Sincerely,

Chris Adams

President and Chief Executive Officer

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/6f570d19-4e9d-47e8-8394-d1a9836b90a2

https://www.globenewswire.com/NewsRoom/AttachmentNg/762f4995-2e4e-481b-af6e-896be990784b

https://www.globenewswire.com/NewsRoom/AttachmentNg/7166ed7f-f7c9-4634-9876-00c8523736a1

https://www.globenewswire.com/NewsRoom/AttachmentNg/e35c8fb8-d44f-4564-96ff-1ddc8c471e6d

https://www.globenewswire.com/NewsRoom/AttachmentNg/532f9651-8c65-40e0-aeb8-41f8b59c9e1e

https://www.globenewswire.com/NewsRoom/AttachmentNg/1790806c-362d-4c4e-94d5-09da442b2e64

https://www.globenewswire.com/NewsRoom/AttachmentNg/3f36dd8c-db9f-47d7-b710-5d2eb2e6b364

LAS VEGAS, Sept. 28, 2026 (GLOBE NEWSWIRE) — Galaxy Gaming, Inc.® (OTC: GLXZ), the world’s leading independent developer and distributor of casino table games and technology, today announced that MONOPOLY® Table Games Progressive has been named Product Innovation of the Year at the Global Gaming Awards Americas 2026, held in Las Vegas.

MONOPOLY Table Games Progressive, developed through Galaxy Gaming’s exclusive licensing agreement with Hasbro®, transforms one of the world’s most recognizable brands into a linked progressive table game experience. Since launch, the game has quickly become one of the industry’s most talked-about new products, with installations now spanning North America and EMEA.

“This recognition means a great deal to our entire team,” said Matt Reback, President and CEO of Galaxy Gaming. “MONOPOLY Table Games Progressive set out to prove that a licensed brand and a progressive jackpot could come together in a way that’s genuinely new and exciting for the casino floor, and this award confirms that players and operators feel the same way. It’s especially meaningful to receive it during G2E week, as we introduce the next chapter of that innovation with MONOPOLY Building Riches, Spotlight Spin Progressive, and Galaxy Link.”

Now in its second decade, the Global Gaming Awards Americas is produced by Gaming America and Gambling Insider and is regarded as one of the gaming industry’s most prestigious honors. Winners are selected by a panel of C-level industry executives, with the voting process independently overseen to ensure transparency and fairness.

Claire Hunter Gregson, Director, Business Development at Hasbro, shared, “MONOPOLY holds a unique position in casino gaming, with a level of recognition and enduring appeal few third-party brands can match. This award is a strong reflection of that brand strength and of Galaxy Gaming’s innovation in bringing MONOPOLY to life on the casino floor.

The award comes as Galaxy Gaming exhibits at G2E 2026, running September 28 through October 1 at the Venetian Expo. At booth #4452, attendees can see MONOPOLY Table Games Progressive alongside its newest MONOPOLY-branded successor, MONOPOLY Building Riches™, as well as Spotlight Spin Progressive™ and Galaxy Link™, the connective technology linking both new games together.

Visit Galaxy Gaming at booth #4452 during G2E 2026 to experience the award-winning MONOPOLY Table Games Progressive alongside MONOPOLY Building Riches™, Spotlight Spin Progressive™, and Galaxy Link™.
Hasbro, MONOPOLY, and Yahtzee are trademarks of Hasbro Inc. group. All other trademarks are the property of their respective owners.

About Galaxy Gaming

Headquartered in Las Vegas, Nevada, Galaxy Gaming (galaxygaming.com) develops and distributes innovative games, bonusing systems, and technology solutions to physical and online casinos worldwide. Galaxy Gaming offers games proven to perform, developed by gaming experts and backed by the highest level of customer support. Galaxy Gaming Digital is the world’s leading licensor of proprietary table games to the online gaming industry. Galaxy Gaming has over 140 licenses worldwide, including licenses in 28 U.S. states and more than 30 countries around the world.

Contact:

Media: 
Phylicia Middleton (702) 938-1753 

Investors:         
Steve Kopjo (702) 727-8886